Program
Anti-CNTN4 Monoclonal Antibody GENA-104A16
Also written as “BI-1607” and “GENA-104A16”.
Its studies are mostly in Uveal Melanoma · Breast Neoplasms, led by 2 companies.
Drug pageAnti-CNTN4 Monoclonal Antibody GENA-104A16: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioInvent International ABits history only | 21 open or running | phase 2since Sep 22, 2022 | Sep 22, 2022 | none ahead |
| Genomeits history only | 10 open or running | phase 1since Jan 15, 2024 | Jan 15, 2024 | none ahead |
Also a collaborator on its studies: Merck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 22, 2022First study: phase 2 study in HER2-positive Breast CancerNew to BioInvent International ABBioInvent International AB · NCT05555251 · 18 enrolled · Germany, Spain, United Kingdom
- Jan 15, 2024Genome’s first study: phase 1 study in Advanced Solid TumorsNew to GenomeGenome · NCT06235541 · South Korea
- Dec 16, 2024Phase 2 study in MelanomaBioInvent International AB · NCT06784648 · 35 enrolled · Germany, Spain, United Kingdom
TargetBeta
“An affinity-matured humanized monoclonal antibody directed against the inhibitory immune checkpoint protein contactin 4 (contactin-4; CNTN4), ”NCIt, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06784648Melanoma · Germany, Spain, United Kingdom | 2 | Active, not recruiting | BioInvent International AB | Sep 9, 2026 | 35 |
| NCT06235541Advanced Solid Tumors · South Korea | 1 | Withdrawn | Genome | Sep 2026 | 0 |
| NCT05555251HER2-positive Breast Cancer · Germany, Spain, United Kingdom | 2 | Terminated | BioInvent International AB | Feb 7, 2024 | 18 |
How it is read
Names in the registry
- “BI-1607”, 3 entries
- “GENA-104A16”, 1 entry
Conditions, from the studies’ own filings
- Uveal Melanoma, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.